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Anticoagulation with enoxaparin versus
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Background: The use of postoperative anticoagulation is not uncommon for patients undergoing vascular procedures,
whether for adjunctive therapy to the surgical procedure or for resumption of preoperative anticoagulation. We
investigated whether low–molecular-weight heparin, specifically enoxaparin, was an effective replacement for intravenous
heparin during the postoperative period until achievement of a therapeutic international normalized ratio, together with
the impact on postoperative length of stay.
Methods: We retrospectively examined 330 patients who received either traditional intravenous unfractionated heparin
with adjusted-dose warfarin daily (n  169) or subcutaneous low–molecular-weight heparin, specifically enoxaparin 1
mg/kg every 12 hours, with adjusted-dose warfarin daily (n  161). Safety was defined as incidence of bleeding,
hematoma, stroke, expiration, thrombocytopenia, return to surgery for graft thrombosis or hematoma, and readmission
within 30 days for hematoma or thrombosis.
Results: For all procedures, regardless of type of anticoagulation treatment, there was no difference in the incidence of
postoperative complications, except for the increased incidence of return to surgery for graft thrombosis (P .02), failing
graft (P  .0004), and debridement (P  .01) in patients who received unfractionated heparin. For all procedures
combined, the average postoperative length of stay was shortened by 2 days with use of low–molecular-weight heparin (P
 .0001).
Conclusions: In this series, use of enoxaparin appears to be safe and effective for vascular postoperative anticoagulation. At
the same time, its use can significantly reduce the average postoperative length of stay for patients undergoing vascular
procedures. Further prospective data are needed before this protocol can be accepted as an alternative for postoperative
anticoagulation in this set of patients. (J Vasc Surg 2002;36:341-5.)
The use of postoperative anticoagulation is not uncom-
mon for patients who are undergoing vascular procedures,
either for adjunctive therapy to the surgical procedure or
for resumption of preoperative anticoagulation. Adjunctive
therapy may be indicated for procedures with extremely
disadvantaged run-off or with less-than-ideal conduits. In
addition, patients with a history of atrial fibrillation/flutter
or valve replacement or of prior revascularization will re-
quire appropriate management to resume their preopera-
tive level of anticoagulation. Traditionally, such manage-
ment postoperatively involves the use of unfractionated
heparin (UFH) with concurrent use of dose-adjusted war-
farin. In-hospital intravenous heparin has been used as a
bridge until an adequate international normalized ratio
(INR) is achieved. This, however, has contributed to a
delay in the postoperative discharge, that occurs while
waiting for the patient’s INR to become therapeutic.
Numerous studies have reported the safety and efficacy
of using low–molecular-weight heparin (LMWH) for a
variety of venous disorders such as prevention of deep vein
thrombosis (DVT) in patients undergoing hip or knee
replacement surgery and abdominal surgery, as well as the
treatment of DVT in outpatient settings.1-7 These data
have also demonstrated the safety and efficacy of using
LMWH for the transition to warfarin as well as significant
cost savings. Furthermore, recent data on the possible use
of LMWH in acute coronary syndromes have suggested
that its role may be extended to vascular beds other than the
venous system.8-10
Despite the use of LMWH in prophylaxis and treat-
ment of these disorders, its role in vascular surgery remains
unclear. Can patients undergoing arterial revascularization
who require long-term anticoagulation be treated as out-
patients by using LMWH administered in conjunction with
warfarin in a manner analogous to its use in the venous
disease processes? This article reviews our experience with
the two methods of anticoagulation following vascular
procedures as a bridge to achieving an adequate INR. We
examined whether LMWH was an effective replacement for
intravenous heparin and its impact on postoperative length
of stay (LOS).
METHODS
This retrospective study included a review of proce-
dures listed in the vascular surgery service database of an
academic medical center and included only procedures that
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resulted in inpatient admissions. Patients with venous dis-
orders were excluded. Anticoagulation was initiated in all
patients with UFH for 24 hours, which was then either
continued until the INR was therapeutic or changed to
LMWH when the patient’s medical condition allowed dis-
charge. We noted, as other investigators have suggested, a
higher incidence of wound hematoma if LMWH was
started before 24 hours. Postoperative anticoagulation
therapy was classified as either (1) UFH, which consisted of
traditional intravenous UFH with adjusted-dose warfarin
daily, or (2) LMWH, which consisted of enoxaparin 1
mg/kg every 12 hours, administered subcutaneously with
adjusted-dose warfarin daily.
This LMWH protocol was started in December 1998.
Later in the course of this series, patients were placed
preferentially on LMWH if all of the components of out-
patient therapy could be set up. If the home care could not
be set up, or the primary care physician and patient would
not agree to the protocol, or the insurance company could
not be convinced to pay for the LMWH, then the patient
was placed on the UFH protocol. For example, in 2000, 68
patients were placed on the UFH protocol and 84 on
LMWH. Blood was drawn daily for inpatients to determine
complete blood counts, activated partial thromboplastin
time (aPTT), and prothrombin time (PT). Therapeutic
goals for the aPTT and INR were 2.5 to 3.5 and 2.0 to 3.0
times control, respectively. Safety was defined as incidence
of bleeding, hematoma, stroke, death, thrombocytopenia,
return to surgery for graft thrombosis or hematoma, and
readmission within 30 days for hematoma or thrombosis.
The assessment of arterial graft patency was measured
by arterial graft duplex after the procedure at 1 week, 3
months, 6 months, 9 months, and 12 months, and every 6
months thereafter. Hematoma was assessed by clinical ex-
amination. INR greater than 3.5 was considered elevated.
Hemorrhage was measured by a fall in hematocrit and was
quantitated by transfusions of either red blood cells and/or
fresh frozen plasma after 8 hours of completion of the
procedure. Hospital LOS was measured as postoperative
LOS after the procedure to discharge from our facility. For
patients with multiple procedures during one hospitaliza-
tion, a separate LOS was calculated between each proce-
dure.
The entire group of patients needing postoperative
anticoagulation was examined. The purpose of combining
these data is to provide a global picture of the possible
savings for multiple procedures that would be encountered
on a vascular service. In addition, the vascular procedures
were further subdivided into four groups, femoral-popliteal
(fem-pop), femoral-distal (fem-distal), carotid endarterec-
tomy (CEA), and other. Other included debridements,
arteriovenous fistula, embolectomy, patch angioplasty, and
iliofemoral and axillary-bifemoral bypass, among others.
The average postoperative LOS and complication rates
were compared for both types of anticoagulation. Differ-
ences were examined with use of the 2, 2-tailed Fisher
exact, and 2-tailed alternate t tests for frequency contin-
gency tables, as appropriate. Statistical significance was set
at P  .05.
RESULTS
During May 1998 to August 2001, our review revealed
5213 procedures in the vascular surgery database. Postop-
erative anticoagulation (330 patients, 6%) was indicated for
either adjunctive therapy (n  259 procedures in 228
patients) or resumption of preoperative therapy (150 pro-
cedures in 102 patients). This percentage has been rela-
tively consistent from year to year. The sample consisted of
53% men with an average age of 71 years (range, 41 to 91
years). Comorbidities most frequently reported included
hypertension (83%) and diabetes (68%). Both hypertension
and diabetes were present in 49% of patients. There was no
statistically significant difference in age, gender, diabetes,
and hypertension distributions between the four subgroups
(Table I). No episodes of severe thrombocytopenia were
noted in this series.
For all procedures, regardless of the type of anticoagu-
lation treatment, there was no difference in the incidence of
postoperative complications, except for the increased inci-
dence of return to surgery for graft thrombosis (P  .02),
Table I. Demographics of each group
Variable
UFH
(n  169)
LMWH
(n  161) P value
Mean age  SD, y 72  12 71  14 .68
Male 83 (49) 84 (57) .09
DM 118 (69) 98 (67) .32
HTN 142 (84) 123 (83) .53
Data are n (%) unless otherwise indicated. N  330.
DM, Diabetes mellitus; HTN, hypertension.
Table IIa. Complications following vascular procedures
according to type of anticoagulation therapy received
Complication
UFH
(n  169)
LMWH
(n  161) P value
RBC 38 36 .69
1INR 9 5 .59
Stroke 0 0 N/A
Expiration 1 2 .60
Return to OR
Graft thrombosis 18 5 .02
Hematoma 8 7 .60
Failing graft 17 3 .004
Debridement 10 1 .01
Dehiscence 1 0 .54
Ischemia 5 3 .75
Readmission
Hematoma 2 7 .09
1INR 0 5 .02
Stenosis 3 2 .60
Graft thrombosis 4 3 .60
Infection 13 8 .60
N  330 patients, 409 procedures.
OR, Operating room; RBC, transfusion of packed red blood cells after 8
hours postprocedure; INR, greater than 3.5 in the postoperative period.
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failing graft (P  .004), and debridement (P  .01) in
patients who received UFH (Tables IIa, IIb). For all pro-
cedures combined, the average postoperative LOS was
shortened by 2 days with the use of LMWH (P  .0001,
Table III). During this period, the average postoperative
LOS was 7 days for patients who received traditional UFH
therapy with adjusted-dose warfarin daily. For patients who
received enoxaparin and adjusted-dose warfarin daily, the
average postoperative LOS was 5 days. When the LOS for
the entire postoperative stay was calculated, decrease in the
LOS for the fem-distal group remained unchanged.
DISCUSSION
These overall data suggest that the use of enoxaparin in
conjunction with warfarin daily has the potential to reduce
hospital LOS and enhance early discharge in postoperative
vascular surgery patients who will be managed with long-
term anticoagulation. However, issues regarding the LOS
in the subgroups warrant further examination. The number
of patients in the CEA group may have been sufficiently
small to produce a type I error. Of note, 46% of these
patients undergoing CEA had resumption of anticoagula-
tion as the reason for postoperative anticoagulation as
compared to 30% of the remainder of the patients. This
suggests that multiple other preexisting medical conditions
may have been present in this subgroup, which may have
contributed to the LOS. Because CEA patients with the
longest stays during the same hospitalization had multiple
intervening medical issues that delayed discharge, these
LOS data may not be as useful. In general, the LOS for
CEA at our institution has been 1.6 days.
In the “other” group, the types of procedures were
diverse, from minor debridement/amputations, arterio-
venous accesses, thrombectomies, and graft revisions, to
axillary-femoral bypasses and aortic procedures. Thus, this
group may have benefitted from further stratification to
identify the patients that may benefit from the use of
LMWH. However, because the numbers are small in each
group, this analysis may not be fruitful in this particular
experience. Finally, in the fem-pop group, a decrease in
Table III. Length of stay (days) with anticoagulation following vascular procedures
All vascular procedures Fem-pop Fem-distal CEA Other
UFH n  215 n  34 n  66 n  19 n  96
x  7  0.42 x  6  0.69 x  8  0.49 x  3  0.46 x  6  .510
LMWH n  194 n  43 n  48 n  19 n  84
x  5  0.4 x  5  0.3 x  6  0.48 x  3  0.85 x  6  .54
Total n  409 n  77 n  114 n  38 n  180
P .0001 .30 .004 1.0 1.0
N  330 patients.
Table IIb. Complications following vascular procedures
Group
Group I
Fem-pop
(n  77)
Group II
Fem-distal
(n  114)
Group III
CEA
(n  38)
Group IV
other
(n  180)
All
(n  409)
RBC 14 37 1 0 52
1INR 3 4 4 3 14
Stroke 0 0 0 0 0
Expiration 1 0 1 1 3
Return to OR
Graft thrombosis 6 2 2 13 23
Hematoma 6 4 1 4 15
Failing graft 1 12 0 7 20
Debridement 2 3 0 6 11
Dehiscence 0 1 0 0 1
Ischemia 2 3 0 3 8
Readmission
Hematoma 4 1 1 3 9
1INR 1 0 2 2 5
Stenosis 1 0 1 3 5
Thrombosis 0 3 0 4 7
Infection 4 6 0 11 21
N  330 patients, 409 procedures.
1INR, INR  3.5 in postoperative period; OR, operating room; RBC, transfusion of packed red blood cells after 8 hours postprocedure.
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LOS was suggested with the use of LMWH but was not
statistically significant.
In summary, following the peripheral vascular surgery,
patients placed on enoxaparin can anticipate a reduction in
hospital stay of 2 days. In effect, this allowed patients to be
discharged who had not achieved therapeutic INRs,
thereby allowing them to become therapeutic as outpa-
tients. As a consequence, on our service this year, with 1700
procedures performed  6%  2 days reduction in LOS 
estimated $1000.00/hospital day, the cost savings would
be $204,000 when compared with the traditional conver-
sion to Coumadin using UFH. In the recent era of cost
containment, it would appear that this type of protocol
would be of particular benefit to third party payers and
hospitals, and, therefore, these data suggest that preexisting
protocols need to be reexamined.
In addition, the use of LMWH will reduce the number
of coagulation laboratory tests required as compared to that
for the follow-up of standard heparin therapy. Enoxaparin
can be given on an outpatient basis with full anticoagula-
tion without monitoring of aPTT, thereby avoiding re-
peated phlebotomy in a patient population with multiple
medical problems and often poor quality veins. Because PT
can now be measured with a fingerstick method, the need
for phlebotomy with this protocol may be reduced signifi-
cantly. In addition, we suspect that patient satisfaction
would be greater with earlier discharge, self-injection, and
greater independence. With the recent approval of LW-
MHs specifically designated with a once-a-day dosing with
multiple-dose vials, we suspect that the use of LMWH will
be further facilitated.
However, this experience has also demonstrated some
of the barriers to use of this protocol. The third party payers
most likely to benefit from this type of protocol have, at
times, tried to curtail the use of “costly” LWMHs. Expla-
nations needed for insurance authorization for the new
indication of adjunctive postoperative anticoagulation re-
quires that additional time be spent by the vascular practi-
tioner to justify the medical necessity for this treatment
alternative. Joint efforts of the vascular nurse practitioner
and the case manager are required to construct an outpa-
tient nursing plan for home care instruction and monitor-
ing. Inconsistencies in home care health insurance cover-
age, variability in requirements of prescription plan
coverage, variability in community pharmacy stock/par
levels of LMWH and mail order–only prescription plans are
just a few barriers evident in this type of discharge plan. In
addition, patient anxiety, patient preference, patient re-
fusal, patient noncompliance, and inability to learn self-
injection technique are just a few of the issues that require
resolution before a safe discharge plan can be implemented.
Joint efforts of the inpatient and outpatient teams facilitate
the needed patient education, careful follow-up, and ready
access to health care professionals that result in successful
anticoagulation.
On the other hand, prior studies have examined sepa-
rate issues in postoperative vascular patients. In one study,
the incidence of postoperative deep vein thrombosis (DVT)
after aortic surgery and lower limb revascularization was
assessed. In this prospective randomized trial, prophylactic
effect of enoxaparin was compared to UFH. Two hundred
thirty-three consecutive patients were assigned to three
groups, aortoiliac reconstruction (n  75), aortofemoral
bypass for atherosclerotic disease (n  71), and femoro-
popliteal or femorodistal bypass (n  87). Patients were
analyzed for development of DVT by duplex scanning.
DVT was present in 10 patients in the LMWH group and in
4 patients in the UFH group (8.2 and 3.6%, respectively;
NS). The incidence of DVT was 8% after aortic or aortoiliac
aneurysmectomy, 7% after aortofemoral revascularization,
and 3.4% after femoropopliteal or femorodistal bypass.
After 1-month follow-up, no clinical event or death could
be related to DVT or pulmonary embolism. The investiga-
tors concluded that LMWH is as safe and effective as UFH
in the prevention of DVT.11
In another series, 201 consecutive patients scheduled
for femorodistal reconstructive surgery under general anes-
thesia were enrolled in a randomized multicenter study.
Immediately before arterial cross-clamping, patients were
given an intravenous bolus of either enoxaparin (n  100)
or UFH (n  101). Subsequent treatment consisted of
subcutaneous administration of LMWH or UFH, begin-
ning 8 hours after the intravenous injection and then every
12 hours thereafter for 10 days. The primary endpoint was
graft patency on day 10 after surgery, as assessed clinically
and/or by postoperative arteriography during reinterven-
tion and/or autopsy. The data showed that graft thrombo-
sis occurred in 8% of patients in the LMWH group and 22%
in the UFH group (P  .009). There were no statistically
significant differences between the two groups in terms of
safety. No differences were detected in other major com-
plications, and it was determined that LMWH was more
effective than UFH when used for the prevention of early
graft thrombosis in patients undergoing femorodistal re-
constructive surgery.12-15
Although these types of data suggest the safety of
LMWH, they do not address many of the discharge plan-
ning issues. In our service we attempted to examine some of
these discharge planning issues. In addition, because we do
not use epidural catheters in our patients, the fact that the
use of the LMWHs may increase the rate of epidural
hematomas with these catheters was not an issue at our
institution but may be a significant issue at other centers.
Although these limited retrospective data suggest the
safety and efficacy of LMWH usage in the perioperative
period, we attempted to examine complications including
bleeding, thrombosis, stroke, and death up to day 30, as
well as readmission within 30 days for thrombosis or hema-
toma, in the clinical use of enoxaparin as the bridge to
achieving an adequate INR in patients undergoing recon-
structive vascular surgery. However, most of the LMWH
patients were indeed receiving UFH until they were medi-
cally stable for discharge. This may have led to the lack of
difference in the complication rates, but would further
accentuate the differences in LOS. Some of the issues that
remain unanswered are the exact cost savings, nursing care
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issues, and patient satisfaction. On the basis of these data,
we suggest that further prospective data are needed before
this protocol can be accepted as an alternative for postop-
erative anticoagulation in this set of patients.
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